Н. В. Коваленко

4.0k total citations
25 papers, 167 citations indexed

About

Н. В. Коваленко is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Н. В. Коваленко has authored 25 papers receiving a total of 167 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Н. В. Коваленко's work include Cancer Treatment and Pharmacology (5 papers), Neutropenia and Cancer Infections (4 papers) and HER2/EGFR in Cancer Research (4 papers). Н. В. Коваленко is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Neutropenia and Cancer Infections (4 papers) and HER2/EGFR in Cancer Research (4 papers). Н. В. Коваленко collaborates with scholars based in Russia, United Kingdom and Germany. Н. В. Коваленко's co-authors include Martin Gore, Laurence Gladieff, Bengt Tholander, Ulrich Freudensprung, Giovanni Scambia, Sandro Pignata, Ana Oaknin, Antonio González-Martı́n, Julian Perez Ronco and Igor Bondarenko and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Н. В. Коваленко

20 papers receiving 164 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Н. В. Коваленко Russia	8	84	48	46	38	28	25	167
Justin Harold United States	8	73 0.9×	38 0.8×	33 0.7×	20 0.5×	48 1.7×	18	186
Sandrine Richard France	8	100 1.2×	18 0.4×	18 0.4×	56 1.5×	39 1.4×	22	188
Jean‐François Tamby United States	4	63 0.8×	79 1.6×	20 0.4×	6 0.2×	43 1.5×	9	170
Hanmei Lou China	6	96 1.1×	16 0.3×	42 0.9×	17 0.4×	19 0.7×	14	154
Ronaldo Lúcio Rangel Costa Brazil	8	45 0.5×	63 1.3×	15 0.3×	17 0.4×	27 1.0×	12	191
Anders Krog Vistisen Denmark	4	193 2.3×	133 2.8×	32 0.7×	10 0.3×	70 2.5×	4	254
Jack Junjie Chan Singapore	7	123 1.5×	14 0.3×	11 0.2×	17 0.4×	50 1.8×	26	189
Zorawar S. Noor United States	7	63 0.8×	21 0.4×	14 0.3×	13 0.3×	48 1.7×	14	172
Song-Nan Chow Taiwan	7	91 1.1×	57 1.2×	106 2.3×	11 0.3×	40 1.4×	9	308

Countries citing papers authored by Н. В. Коваленко

Since Specialization

Citations

This map shows the geographic impact of Н. В. Коваленко's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Н. В. Коваленко with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Н. В. Коваленко more than expected).

Fields of papers citing papers by Н. В. Коваленко

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Н. В. Коваленко. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Н. В. Коваленко. The network helps show where Н. В. Коваленко may publish in the future.

Co-authorship network of co-authors of Н. В. Коваленко

This figure shows the co-authorship network connecting the top 25 collaborators of Н. В. Коваленко. A scholar is included among the top collaborators of Н. В. Коваленко based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Н. В. Коваленко. Н. В. Коваленко is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Коваленко, Н. В., et al.. (2024). Prediction of pancreatic fstula after pancreatoduodenectomy using machine learning. SHILAP Revista de lepidopterología. 22(6). 25–34.

Kit, Oleg I., et al.. (2023). Bioinformational and clinical aspects of identificationof differentially expressed genes by tumor cells in endometrialcarcinoma and rare forms of uterine body cancer. Medical news of the North Caucasus. 18(1).

Коваленко, Н. В., et al.. (2022). Gastric cancer in patients aged younger and older than 50 years: characteristics of gastric cancer and survival analysis. SHILAP Revista de lepidopterología. 21(2). 24–37. 1 indexed citations

Коваленко, Н. В., et al.. (2021). Surgical Treatment of Gastric Malignancy in Chronic Kidney Disease Patient with Long-Term Haemodialysis. SHILAP Revista de lepidopterología. 11(4). 337–342.

Коваленко, Н. В., et al.. (2021). Submental Myodermal Flap in Buccal Reconstruction after Extended Combined Resection. SHILAP Revista de lepidopterología. 11(2). 132–137.

Reck, Martin, Alexander Luft, Igor Bondarenko, et al.. (2020). A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. Lung Cancer. 146. 12–18. 17 indexed citations

Коваленко, Н. В., et al.. (2020). Distal subtotal gastrectomy and gastreectomy in surgical treatment of patients with gastric cancer: a systematic review and meta-analysis. Pirogov Russian Journal of Surgery. 93–93. 2 indexed citations

Коваленко, Н. В., et al.. (2020). A METHOD FOR RESTORING VOICE FUNCTION OF THE LARYNX AFTER OPERATIONS FOR THYROID CANCER. Journal of Volgograd State Medical University. 17(3). 120–122. 1 indexed citations

Коваленко, Н. В., et al.. (2020). FIVE-YEAR EXPERIENCE OF LAPAROSCOPIC SURGERIES FOR COLORECTAL CANCER. Journal of Volgograd State Medical University. 17(1). 76–79. 1 indexed citations

10.

Reck, Martin, Alexander Luft, Igor Bondarenko, et al.. (2019). A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC. Annals of Oncology. 30. v644–v645. 2 indexed citations

11.

Ledermann, JA, Jalid Sehouli, Bogdan Żurawski, et al.. (2017). A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma. Annals of Oncology. 28. v626–v626. 13 indexed citations

12.

Nechaeva, Marina, Olga Burdaeva, Vladimir Vladimirov, et al.. (2015). Efficacy and safety of empegfilgrastim, a novel pegylated G-CSF: Results of complete analysis after 4 cycles of myelosuppressive chemotherapy in phase III double-dummy randomized clinical study.. Journal of Clinical Oncology. 33(15_suppl). e20735–e20735. 5 indexed citations

13.

Коваленко, Н. В., et al.. (2015). To the question of complex treatment of endometriosis. Reproductive Endocrinology. 0(23). 28–28. 1 indexed citations

14.

Orlov, Sergey, Olga Burdaeva, М. В. Копп, et al.. (2014). Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin in patients.. Journal of Clinical Oncology. 32(15_suppl). e13500–e13500. 11 indexed citations

15.

González-Martı́n, Antonio, Laurence Gladieff, Bengt Tholander, et al.. (2013). Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. European Journal of Cancer. 49(18). 3831–3838. 43 indexed citations

16.

Chernovskaya, T.V., Olga Burdaeva, Marina Matrosova, et al.. (2013). Efficacy and safety of BCD-017, a novel pegylated filgrastim: Results of open-label controlled phase II study in patients with breast cancer receiving myelosuppressive chemotherapy.. Journal of Clinical Oncology. 31(15_suppl). e20593–e20593. 5 indexed citations

17.

Hickish, Tamas, Minish Jain, Chiun‐Sheng Huang, et al.. (2012). Abstract OT1-1-17: LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib*. Cancer Research. 72(24_Supplement). OT1–1. 3 indexed citations

18.

Hegg, Roberto, Tadeusz Pieńkowski, Elżbieta Starosławska, et al.. (2012). Immunogenicity of Trastuzumab Intravenous and Subcutaneous Formulations in the Phase III Hannah Study. Annals of Oncology. 23. ix103–ix103. 6 indexed citations

19.

González-Martı́n, Antonio, Laurence Gladieff, Bengt Tholander, et al.. (2012). Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): Results from OCTAVIA.. Journal of Clinical Oncology. 30(15_suppl). 5017–5017. 7 indexed citations

20.

Muñoz-Mateu, Montserrat, Ander Urruticoechea, Robert Šeparović, et al.. (2011). Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, phase II study (PHEREXA).. Journal of Clinical Oncology. 29(15_suppl). TPS118–TPS118. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact